Patents by Inventor Daisuke Akazawa
Daisuke Akazawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250069858Abstract: [Object] To provide a plasma processing apparatus capable of expanding an formation region of plasma generated on an upper electrode side to increase the processing speed and a control method therefor. [Solving Means] A plasma processing apparatus according to an embodiment of the present invention includes a vacuum chamber, a substrate-supporting stage, a counter electrode, and a resonant circuit. The substrate-supporting stage is disposed inside the vacuum chamber and is connected to a first high-frequency power supply circuit that supplies a high-frequency power at a first frequency. The counter electrode is disposed in opposite to the stage and is connected to a second high-frequency power supply circuit that supplies a high-frequency power at a second frequency. The resonant circuit allows high-frequency current at the second frequency from the counter electrode to pass therethrough.Type: ApplicationFiled: August 16, 2024Publication date: February 27, 2025Inventors: Kenta DOI, Toshiyuki NAKAMURA, Yasuhiro MORIKAWA, Kensuke AKAZAWA, Daisuke HIRONIWA
-
Publication number: 20240325529Abstract: A medicament characterized by comprising: an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein; a pyrimidine-based drug; a platinum formulation; and an angiogenesis inhibitor together or separately in combination is useful as a medicament for treatment and/or prevention of a cancer of a cancer patient having a medical history of another treatment of the cancer.Type: ApplicationFiled: June 22, 2022Publication date: October 3, 2024Applicant: TORAY INDUSTRIES, INC.Inventors: Fumiyoshi OKANO, Daisuke AKAZAWA
-
Publication number: 20230165957Abstract: An object of the present invention is to provide a medicament for treatment and/or prevention of cancer. The present invention provides a medicament for treatment and/or prevention of cancer in a cancer patient with a previous history of another cancer treatment, comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a pyrimidine-based drug and cisplatin together or separately in combination.Type: ApplicationFiled: March 11, 2021Publication date: June 1, 2023Applicant: TORAY INDUSTRIES, INC.Inventors: Fumiyoshi OKANO, Daisuke AKAZAWA
-
Publication number: 20230129035Abstract: An object of the preset invention is to provide a medicament for treatment and/or prevention of cancer. The present invention relates to a medicament for treatment and/or prevention of cancer in a cancer patient with a previous history of another cancer treatment, comprising an antibody or a fragment thereof haying an immunological reactivity with CAPRIN-1 protein, and an angiogenesis inhibitor or an angiogenesis inhibitor and a taxane-based drug together or separately in combination.Type: ApplicationFiled: March 11, 2021Publication date: April 27, 2023Applicant: TORAY INDUSTRIES, INC.Inventors: Fumiyoshi OKANO, Daisuke AKAZAWA
-
Patent number: 8776927Abstract: A vehicle battery pack housing structure includes a vehicle body panel and first, second and third panel components that define an outward-opening battery housing space. The first panel component is rigidly attached to the vehicle body panel and includes a first side wall and a base wall. The second panel component is rigidly attached to the first panel component and includes a second side wall and a first periphery wall portion. The third panel component is rigidly attached to the second panel component. The third panel component includes a second periphery wall portion that cooperates with the first periphery wall portion to form a periphery wall portion when the third panel component is rigidly attached to the second panel component.Type: GrantFiled: May 23, 2011Date of Patent: July 15, 2014Assignee: Nissan Motor Co., Ltd.Inventors: Daisuke Akazawa, Yasutsune Terashima
-
Publication number: 20140046034Abstract: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.Type: ApplicationFiled: October 22, 2013Publication date: February 13, 2014Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, TORAY INDUSTRIES, INC.Inventors: Takaji WAKITA, Kazumi NISHIMURA, Noriko NAKAMURA, Daisuke AKAZAWA
-
Patent number: 8604179Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: GrantFiled: April 24, 2009Date of Patent: December 10, 2013Assignees: Toray Industries, Inc., Japan As Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Organization for Medical ResearchInventors: Daisuke Akazawa, Takaji Wakita
-
Patent number: 8592559Abstract: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.Type: GrantFiled: October 29, 2010Date of Patent: November 26, 2013Assignees: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious DiseasesInventors: Takaji Wakita, Kazumi Nishimura, Noriko Nakamura, Daisuke Akazawa
-
Publication number: 20130068548Abstract: A vehicle battery pack housing structure includes a vehicle body panel and first, second and third panel components that define an outward-opening battery housing space. The first panel component is rigidly attached to the vehicle body panel and includes a first side wall and a base wall. The second panel component is rigidly attached to the first panel component and includes a second side wall and a first periphery wall portion. The third panel component is rigidly attached to the second panel component. The third panel component includes a second periphery wall portion that cooperates with the first periphery wall portion to form a periphery wall portion when the third panel component is rigidly attached to the second panel component.Type: ApplicationFiled: May 23, 2011Publication date: March 21, 2013Applicant: NISSAN MOTOR CO., LTD.Inventors: Daisuke Akazawa, Yasutsune Terashima
-
Publication number: 20120251572Abstract: A combination of an HCV antigen for inducing an antibody having the activity of inhibiting HCV infection and an optimum adjuvant is discovered, so as to provide an effective HCV vaccine composition. The hepatitis C virus vaccine composition comprises: inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain; an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and aluminium hydroxide.Type: ApplicationFiled: September 30, 2010Publication date: October 4, 2012Inventors: Takaji Wakita, Masaki Moriyama, Daisuke Akazawa, Noriko Nakamura
-
Publication number: 20120220758Abstract: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.Type: ApplicationFiled: October 29, 2010Publication date: August 30, 2012Inventors: Takaji Wakita, Kazumi Nishimura, Noriko Nakamura, Daisuke Akazawa
-
Publication number: 20110045020Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: ApplicationFiled: April 24, 2009Publication date: February 24, 2011Inventors: Daisuke Akazawa, Takaji Wakita
-
Publication number: 20100291545Abstract: The objection of the invention is to provide an antibody that inhibits infection with hepatitis C virus (HCV).Type: ApplicationFiled: July 25, 2008Publication date: November 18, 2010Inventors: Takaji Wakita, Tetsuro Suzuki, Kenichi Morikawa, Noriaki Omi, Noriko Nakamura, Daisuke Akazawa